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ABSTRACT
The introduction in clinical practice of
pharmaceutical products known as biosimilars,
as part of a more complex series of progress in
the field of biological drugs, represents an
excellent therapeutic resource. A biosimilar
drug is a biological/biotechnological drug that
is highly similar to an approved reference
biologic product. Given their complexity,
biosimilars require attention and a continued
vigilance to ensure appropriate use, especially in
cancer therapy. There is the urgent need, both
at Italian and European levels, of clear and more
comprehensive guidelines to elucidate the open
questions. Probably, the acquisition of new
data, obtained from larger samples of patients
than those used in the pre-approval studies and
with extremely variable clinical conditions, will
allow clarifying the extent to which biosimilar
drugs are similar in safety and efficacy to their
biologic reference drug. The aims of this article
are to provide health professionals with basic,
but essential information about biosimilars, and
to identify current critical points and future
perspectives for clinical practice, cancer care,
regulatory aspects, and pharmacovigilance.
Keywords: Biosimilars; Europe; Oncology;
Pharmacovigilance
INTRODUCTION
A biosimilar is a biological/biotechnological
drug that contains a version of the active
substance of an already authorized original
biological product (reference biologic product)
in the European Economic Area (EEA). The
biosimilar drug is similar to the reference
biologic product in terms of quality
characteristics, biological activity, safety, and
efficacy [1].
Currently, in Europe a pharmaceutical
patent lasts 20 years from the date the patent
protection is issued and may be extended up to
5 additional years [2, 3]. The patents of some
essential biological drugs in oncology,
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monoclonal antibodies (mAbs), have expired
between the years 2013–2014 [4]. This aspect
has opened the door to a competitive market,
which should lead to lower prices of these drugs
by approximately 20–30 % [5]. Indeed, the
complexities in development and production
of biological drugs lead to very high costs.
The potential of biosimilars are twofold: on
the one hand, they represent a new option for
the prevention and treatment of severe and
debilitating diseases and, on the other, thanks
to their improved economic sustainability on
the European health systems, they ease patient
access to innovative medicines.
The aims of this article is to provide health
professionals with basic, but essential
information about biosimilars, and to identify
current critical points and future perspectives
for clinical practice, cancer care, regulatory
aspects, and pharmacovigilance. This article
does not contain any new studies with human
or animal subjects performed by any of the
authors.
SIMILAR BUT NOT IDENTICAL
Biosimilar drugs, put on the market at reduced
costs compared to the originator, are often
considered as generic drugs of lower quality on
the belief that a lower price indicates lower
quality. That view is totally wrong. The
difference between a generic and biosimilar is
clear-cut, and development and regulatory
pathways for marketing approval as biosimilar
drug are even more rigorous than those of a
generic drug (Table 1).
The concept of generic can be associated
with the term bioequivalence. A drug is defined
as generic when it is bioequivalent to the
medicinal product from which it is derived, or
rather:
• Contains the same quantity and quality of
active ingredients (however, the excipients
may vary);
• Presents the same dosage and method of
administration;
• Has equivalent bioavailability;
• Produces the same clinical effects and,
therefore, has the same therapeutic
indications.
The generic drug is a copy of the ‘brand
name’ product from which it is derived and
whose patent is expired. The manufacturing of a
generic drug is made by chemical synthesis
through standardized and reproducible
procedures, and it is the same as the originator
drug. Consequently, the process of marketing
authorization is simplified; the producer
presents a dossier on a generic drug to the
regulatory authority in charge of approving it
(in Italy, Agenzia Italiana del Farmaco, AIFA);
the dossier must contain the data proving the
quality and bioequivalence of the generic drug.
The quantitative evaluation of
bioequivalence is based on the
pharmacokinetic parameters assessing drug
absorption and spread throughout the body
through the bloodstream. According to the
guidelines issued by the European Medicines
Agency (EMA) [6], 90 % of the confidence
interval [derived from the ratio of the average
values of the parameters Cmax (maximum serum
concentration) and AUC (area under the curve)]
must fall within the range of acceptability
(80–125 %). However, the manufacturer of the
drug is not required to repeat the studies on
safety and effectiveness because these have
already been proven by the reference medicine.
Conversely, for the biosimilar drug
everything is based on biosimilarity. The
biosimilar and its reference product must be
comparable regarding quality, safety, and
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efficacy. The biosimilar, being similar but not
identical to its originator, may differ both in
form and in structure: It is obtained from
irreproducible production processes subject to
variability (the drug is obtained from living
organisms, which are more complex than a
simple chemical molecule) [7]. For biosimilars,
the plasma production process markedly affects
the safety profile and efficacy of the drug [8].
Moreover, the current legislation states that the
manufacturer of a particular originator drug
holds the patent on the techniques of
production, and; therefore, there may be
substantial differences between the biosimilar
and its reference product.
It is clear that the biosimilar is not a generic
drug and, as such, cannot be approved by a
simplified dossier [1]. In 2005, the EMA
proposed guidelines for biosimilars [8]; the
biosimilar must undergo a series of studies to
compare it to its originator drug and to obtain
marketing authorization. Together, these
studies are defined as Comparability Exercise
[1], which initially consists of studies on quality
(biological and physic–chemical comparisons);
then continues with comparative non-clinical
Table 1 Comparison of a generic drug versus biosimilar drug
Generic drug Biosimilar drug
Production
Synthesis Chemical Biological
Structural features Little and structurally simple
molecules
Large and structurally complex
molecules
Production process Standard chemical synthesis Speciﬁc using living cells
Immunogenicity risk Low High
Regulation
Identity with reference product Bioequivalent to the reference product Biosimilar to the reference product
Dossier Simpliﬁed dossier Full quality dossier
Comparability exercise with reference No Yes
Use
Interchangeability Yes EMA does not address the issue
Substitutability Yes EMA does not address the issue
Nomenclature Refers to INN names There is not a speciﬁc legislation
Safety and pharmacovigilance
ADRs report form Report the INN name and
manufacturer
Report the brand name and
batch number
Risk management plan (RMP) No Yesa
Additional monitoring No Yesa
ADR adverse drug reaction, EMA European Medicines Agency, INN international nonproprietary name
a Module SI [epidemiology of the indication(s) and target population(s)] is not required
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studies (toxicity, pharmacokinetics, and
pharmacodynamics), to end with clinical trials
(efficacy and clinical safety, including
immunogenicity). The aim is to demonstrate
that, despite the intrinsic variability, the
biosimilar has no significant clinical difference
(of efficacy) compared to its reference product.
The objective of developing a biosimilar drug is
the similarity with the originator regarding
efficacy, safety, and quality.
It should be noted that given the complex
molecular structure of biological drugs
(including biosimilars), every little change
during its production, transport, and storage
can result in significant differences in efficacy
and clinical safety. Therefore, the regulatory
authorities (AIFA and EMA) conduct rigorous
inspections to ensure strict compliance with
good manufacturing practice (GMP) and good
distribution practice (GDP) [8].
BIOSIMILARS IN ONCOLOGY
In Europe, the first biosimilars to enter into
clinical practice were erythropoiesis stimulating
agents (ESAs) (e.g., epoetin alfa) and colony
stimulating factors (CSFs) (e.g., filgrastim) [9].
These biosimilars are considered ‘‘first
generation’’ biopharmaceuticals, and they are
used in supportive care, for example, to reduce
the occurrence of neutropenia associated with
cancer treatment.
The mAbs drugs, an even more innovative
category of biopharmaceuticals, has successfully
entered oncologic clinical practice several years
ago, proving useful in treatment of several
cancers. These mAbs ‘second-generation’
biopharmaceuticals are large proteins, much
more complex than the simple proteins
present in first generation biopharmaceuticals,
which are produced through genetic
engineering. Consequently, the mAbs are to be
considered in all aspects biotechnological
medicinal products. Their anti-tumor activity
is carried out on molecular targets, which are
molecules or receptors located within the cell
and are involved in the growth, angiogenesis,
and cell proliferation. There are many
advantages to using mAbs in oncology. First
and foremost, these drugs can cause a
considerable enhancement for chemotherapy
and conventional therapies. Secondly, because
of their improved selectivity against cancer
cells, mAbs cause less toxicity to healthy cells,
although side effects directly associated with
their use are also present [10].
In 2013, the EMA approved Remsima
(Celltrion Healthcare Hungary Kft) and
Inflectra (Hospira UK Ltd.), which are
biosimilars of infliximab, a mAb used for the
treatment of inflammatory diseases (e.g.,
rheumatoid arthritis, Crohn’s disease,
ulcerative colitis) [11].
Currently, in Europe there are no biosimilar
mAbs available to treat neoplastic diseases;
however, it is only a matter of time. Some of
these drugs are already in the final stages of
clinical trials. The following or already expired
patent of many mAbs commonly used in the
treatment of cancer (e.g., rituximab and
trastuzumab), will make short-term
biosimilar-based therapies possible [4].
In economically emerging countries such as
India, China, and in South America, the
production of biological drugs is on the rise.
In fact, the need for these accessible and
affordable lifesaving drugs has led these
countries to add biosimilar monoclonal drugs
to their trading market [9].
The extensive introduction of biosimilar
drugs in economically emerging countries into
clinical practices was favored by less stringent
guidelines than European or American ones
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[12]. In India, for instance, Reditux (Dr.
Reddy’s Laboratories) is commonly used.
Reditux is registered as a copy of the patented
rituximab, a mAb for the treatment of
non-Hodgkin lymphomas [13]. The approval
pathway for Reditux in India followed a
single-arm trial and no clinical head-to-head
trials were made. This aspect has been widely
discussed by Qureshi et al. [14]: the authors
emphasize the fact that for biosimilars,
similarity in efficacy and safety with the
reference product must be demonstrated in
adequately large head-to-head clinical trials.
Consequently, not being able to apply the
definition of ‘biosimilar drug’ by the EMA or
by the US Food and Drug Administration (FDA)
to the pharmaceuticals, Reditux cannot be
considered a true biosimilar drug but rather a
me-too drug. A me-too drug is manufactured
following research pathways previously
explored. It is not intended to be operated on
comparability with the reference biological drug
and, consequently, the registration process is
conventional.
BIOSIMILARS: THE NEED
The primary reason for the actual push for
biosimilar drug use is the reduced cost
compared to the originator. The cost reduction
is of paramount importance, especially in
oncology, where the expenditures associated
with antineoplastic agents and
immunomodulators are very high [15],
affecting the sustainability of National Health
Systems: for example, in Italy the costs of
biosimilars are entirely borne by the Sistema
Sanitario Nazionale (SSN) [16]. The
introduction of biosimilar oncology drugs
should have a future impact on the use of
resources; it is believed that the biosimilars may
be priced 20–30 % lower than their originators
[5]. However, one must be aware that the price
will vary and depend on the market, the
competition between manufacturers and
agreements of reimbursement between
regulatory authorities and producers. It is
unlikely that the cost reductions obtainable by
biosimilars may be comparable to those seen in
generic drugs. The development and the
registration procedures of a biosimilar drug are
just as long and complicated as those of a
biological drug, and, therefore, expensive. In
any case, the cost of a biosimilar is still less than
the reference biological product [17], and this
aspect fully justifies the introduction of this
new class of drugs.
CRITICAL ASPECTS OF BIOSIMILAR
ONCOLOGY DRUGS
Study Design
In oncology, the effects of therapy are defined
as endpoints. Some endpoints relate to the
disease and some relate to the patient. These
are fundamental criteria in establishing the
efficacy of a cancer treatment. The EMA, in
the guidelines set for biosimilar mAbs, sets as
primary endpoints: absence of disease; absence
of disease progression; and overall survival. The
goal of clinical trials that leads to the approval
of a biosimilar is to demonstrate that there are
no significant clinical differences with the
reference product [18]; therefore, primary
endpoints must be alike between the two
drugs. In other words, therapeutic equivalence
must be demonstrated, but it is not simple. In
the absence of data, there is a lack of certainty
concerning the equivalence between biosimilar
and its reference; often skepticism or doubt arise
in both patient and physician. To overcome this
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issue, a more accurate assessment of the
endpoints would be required, which should be
as much as possible calibrated on a specific
biosimilar versus its originator in addition to
more extensive clinical trials testing therapeutic
equivalence or non-inferiority of the biosimilar.
Immunogenicity
One of the most important issues regarding
biological medicine, and, thus, also biosimilars,
is its immunogenic potential. Since most
biological drugs are of a protein nature, the
patient to whom the drug is given may develop
antibodies because that protein is recognized as
‘non-self’ [19]. This aspect can affect the
concentration of the drug in the blood and,
therefore, its ability to produce a therapeutic
effect. The immunogenicity can be a clinically
insignificant event, but, even rarely, may cause
serious adverse reactions: immunogenicity may
cause hypersensitivity, anaphylaxis, infusion
reactions, and loss of efficacy [8, 20].
Consequently, this must be evaluated case by
case. The ability of biological drugs to induce
immune responses may depend on several
factors: the particular properties of the
biological molecule, the patient characteristics,
concomitant treatments, the administration
mode or, finally, on changes introduced in
production processes.
In this regard, one of the most sensational
events occurred in the 1990s. The change made
to the formulation of epoetin alfa for
subcutaneous use caused pure red cell aplasia
in different patients. This serious side effect was
produced by replacing serum albumin with
stabilizing agents (polysorbate 80 and glycine)
[21].
The example demonstrates that even a small
change can greatly affect the safety profile of a
biological drug. Therefore, the regulatory
authorities require a drug’s manufacturers to
conduct studies under continuous monitoring
of product safety, both before and after placing
it on the market (so-called post-marketing
studies) [22].
Interchangeability
In certain clinical situations, an oncologist may
decide to replace one drug with another. This
practice is defined as interchangeability. The
interchangeability takes place when the two
drugs are expected to be capable of producing
the same clinical effect. The originator
biological drugs and their biosimilars are
similar, but not necessarily identical
concerning efficacy and toxicity. Therefore, it
cannot be assumed that they are automatically
interchangeable [1].
Interchangeability is a process where the
National Authority decides that drugs of the
same class are interchangeable. The EMA do not
address the issue of interchangeability for
biosimilars, leaving to the medical provider
the decision (and legal responsibility) to
replace one drug with another. Both the EMA
and the AIFA recommend therapeutic
continuity for each patient already being
treated; however, there is no reason not to
prescribe directly biosimilar drugs to naı¨ve
patients, i.e., patients not previously treated.
The EMA approves biosimilar drugs based on
all the same therapeutic indications of the
originators, which, thus, allows extrapolating
data from the studies conducted on the
originator. Extrapolation in cancer therapy,
however, requires extreme caution, as there is
no data on long-term effects. Especially in the
case of biosimilar mAbs used in oncology, a
case-by-case assessment is required as well as a
cautious attitude, in the spirit of ‘‘knowledge
and belief.’’
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Substitutability
Substitutability is conceptually different from
interchangeability. In Italy, the AIFA defines
substitutability [1] as the replacement of a
prescribed drug with a drug that has the
following properties: usually more economical;
bioequivalent, and with the same active
ingredients, form, and dosage.
Substitutability is an active and/or passive
process at the pharmacy level. In Italy, the
replacement can be accomplished by the
pharmacist and is allowed only between drugs
included in the so-called ‘‘price transparency
list’’ issued by the AIFA. Currently, only generic
drugs and their originators appear in these lists.
Therefore, the AIFA excludes the possibility of
automatically replacing a biological medicine
with the biosimilar [1]. Consequently, the
choice to opt for therapy with a biosimilar
drug or with its originator falls again on the
medical provider. Since there are no
standardized rules at the Italian national level,
each Region has implemented individual
measures, creating further confusion and
inequalities in access to care [17].
Another aspect to consider is that the
automatic replacement could generate
misleading correlations between a drug and an
adverse drug reaction (ADR), affecting the
accuracy of data obtained from
pharmacovigilance.
Nomenclature
Usually, the nomenclature of generic drugs
refers to the international nonproprietary
names (INN): the name of the generic drug is
made by the active ingredient followed by the
name of the manufacturer (e.g., olanzapine,
Teva). For biosimilars assignments by the INN
would not be entirely correct: the drug is not
structurally identical to its originator, and the
same INN name might associate products with
different safety profiles [23].
The unique identification of a biosimilar is
necessary for several reasons: first, to ensure the
traceability of the medication; then, to avoid
compromising pharmacovigilance and, above
all, to ensure safety. In fact, the most frequent
errors in therapy by the patient or healthcare
provider are caused by the use of drugs that
have similar names, graphics, or phonetics
(Look Alike-Sound Alike, LASA).
Since 2006 the World Health Organization
(WHO) has been looking for a name for
biosimilars that is universal and more
suitable than the INN names. In Europe, the
choice of resorting to INN to name a biosimilar
lies with the manufacturer, and there is not
specific legislation outlining how the trade
name should be assigned to a biological/
biosimilar drug.
PHARMACOVIGILANCE
Post-marketing surveillance (an essential part of
pharmacovigilance) is the set of
interdisciplinary activities that aims to make
the drug use as safe as possible, i.e., ensuring
that the benefits of the drugs continue to
outweigh the risks even after their marketing.
The task of pharmacovigilance is to detect
potential ADRs or changes in the frequency of
adverse events, which are predictable and
already known, and to implement, if
necessary, specific preventive measures.
Pharmacovigilance monitors, reports and
evaluates all medications, even those that have
been used for a long time or usually used as
self-medication.
The biological and biosimilar drugs are
considered a priority for the activities of the
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pharmacovigilance and, for this reason, the
European Union has included them in the
‘List of Drugs Subject to Additional
Monitoring.’ The identification of these drugs
is by a black, inverted, equilateral triangle in the
Illustrated leaflet and the summary of product
characteristics (SPC) [24].
If there is a suspected ADR, the health
professional must notify the National
Pharmacovigilance Network through the
completion of a report form. Since there may
be differences between biological and biosimilar
drugs, even between different batches of the
same product, the report formmust indicate the
trade name of the drug and the lot number. This
arrangement allows the product alleged to have
caused an ADR to be easily traced [25].
CONCLUSIONS
Given their extreme complexity, biosimilar
drugs must be used wisely in the treatment of
cancer and with proper attention and
awareness. Without a doubt, biosimilars
represent an excellent therapeutic resource at
an affordable cost that should not be
underestimated.
At the European level, there is an urgent
need for more clear and consistent guidelines to
clarify open issues. Unfortunately, knowledge
of these innovative drugs is still imprecise. The
correct and comprehensive information on the
use of biosimilars, especially in oncology,
should be a priority on the part of the
regulators, the media, and health professionals.
The acquisition of new data, obtained from
larger samples of patients than those used in the
pre-approval studies and with extremely
variable clinical conditions, will allow
clarifying the extent to which these drugs are
similar in terms of safety and efficacy to their
biologic reference drug. It is for this reason that
all pharmacovigilance activities will provide a
significant contribution to a deeper
understanding of all aspects characterizing a
biosimilar drug.
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